Vasudha Tandon
Dundee, SCT DD19SY, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Dyr726, a brain-penetrant inhibitor of PI3Kα, Type III receptor tyrosine kinases, and WNT signaling.
Dyr726, a brain-penetrant inhibitor of PI3Kα, Type III receptor tyrosine kinases, and WNT signaling.
Journal: bioRxiv : the preprint server for biology
Published: April 08, 2025
One-pot synthesis of tetrahydropyrimidinecarboxamides enabling in vitro anticancer activity: a combinative study with clinically relevant brain-penetrant drugs.
Journal: RSC advances
Published: June 07, 2024
Dual inhibition of HSF1 and DYRK2 impedes cancer progression.
Journal: Bioscience reports
Published: October 07, 2022
Synthesis of N-(4-chlorophenyl) substituted pyrano[2,3-c]pyrazoles enabling PKBβ/AKT2 inhibitory and in vitro anti-glioma activity.
Journal: Annals of medicine
Published: September 19, 2022
Glasgow Neuro Society 2021 Conference Proceedings.
Journal: Surgical neurology international
Published: March 20, 2022
Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo.
Journal: Bioscience reports
Published: December 01, 2021
Emerging roles of DYRK2 in cancer.
Journal: The Journal of biological chemistry
Published: September 23, 2020
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: November 23, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026